Elicio Therapeutics, Inc.
NASDAQ:ELTXBiotechnology
-$0.89 today
- Market cap
- $51.48M
- Beta
- 1.14
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$2.21
Volume 0.41M
Average 0.34M
ELTX Total Liabilities
Everything the company owes to creditors and other parties.
Elicio Therapeutics, Inc.NASDAQ: ELTX
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities rises 25.4% from a year ago
Total liabilities stood at $24.13M at the end of Q1 FY2026, up 25.4% from a year earlier and down 0.4% from the prior quarter. Over 3 fiscal years it compounded at +20.8% a year.
Context
- Total liabilities amounted to 106.3% of total assets at the end of Q1 FY2026, up 38.0 pp from a year earlier.
- Total liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +25.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 24.23M USD
- Year-over-year change
- -38.7%
- 4-year CAGR
- +12.7%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 24.23M | -38.7% |
| FY2024 | 2024-12-31 | 39.49M | +150.4% |
| FY2023 | 2023-12-31 | 15.77M | +14.7% |
| FY2022 | 2022-12-31 | 13.75M | -8.4% |
| FY2021 | 2021-12-31 | 15.01M | — |
Total Liabilities vs competitors
How ELTX compares with its peers on the latest reported figures
- Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +25.4% is the 4th highest of 9, against a peer median of -1.1%.
- Total liabilities amounts to 106.3% of total assets for ELTX, versus a peer median of 26.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $157.69M USD | +131.9% | +106.7% | 81.4% | |
| Mar 2026 | $86.21M USD | -6.1% | -3.0% | 23.2% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | $24.13M USD | +25.4% | +20.8% | 106.3% |
| Mar 2026 | $22.32M USD | -37.3% | -11.2% | 14.3% | |
| Mar 2026 | CHF 19.15M CHF | +48.4% | -7.0% | 21.9% | |
| Mar 2026 | $18.14M USD | +41.4% | -14.7% | 12.6% | |
| Mar 2026 | $16.34M USD | -44.6% | -20.5% | 31.5% | |
| Mar 2026 | $14.46M USD | +3.8% | +18.8% | 29.4% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $5.13M USD | -46.4% | +2.6% | 57.5% |
| Peer median (excluding ELTX) | — | -1.1% | -5.0% | 26.3% | |
Competitors are the stored peer set for ELTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 88.76M | 7.8M | 12.89M | 17.62M | 18.56M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 806K | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 379K | 36K | 895K | 1.28M | 73K |
| Total Current Assets | 91.25M | 10.72M | 16.35M | 20.69M | 19.31M |
| Property, Plant & Equipment (Net) | 4.44M | 8.5M | 7.28M | 6.19M | 5.08M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 723K | 617K | 0 | 696K | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 106K | 2.83M | 3.52M | 600K | 1.47M |
| Total Non-current Assets | 5.27M | 11.95M | 10.8M | 7.49M | 6.55M |
| Total Assets | 96.51M | 22.66M | 27.15M | 28.18M | 25.86M |
| Account Payables | 4.71M | 2.81M | 4.37M | 1.04M | 672K |
| Short-term Debt | 952K | 692K | 0 | 901K | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 2.3M | 1.44M | 0 | 1.17M | 0 |
| Other Current Liabilities | 2.06M | 444K | 2.57M | 2.31M | 2.53M |
| Total Current Liabilities | 11.3M | 6.87M | 9.76M | 11.52M | 8.11M |
| Long-term Debt | 0 | 0 | 0 | 20.03M | 9.41M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 92K | 11K | 2.83M | 2.62M |
| Total Non-current Liabilities | 3.71M | 6.88M | 6.02M | 27.97M | 16.12M |
| Total Liabilities | 15.01M | 13.75M | 15.77M | 39.49M | 24.23M |
| Common Stock | 300K | 3K | 96K | 110K | 178K |
| Retained Earnings | (215.14M) | (107.01M) | (142.2M) | (194.1M) | (233.67M) |
| Accumulated OCI | (103K) | 0 | (197K) | (175K) | (127K) |
| Other Stockholders Equity | 226.01M | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 81.51M | 8.92M | 11.37M | (11.31M) | 1.64M |
| Total Debt | 4.66M | 7.48M | 6.92M | 26.04M | 14.51M |
| Net Debt | (84.09M) | (316K) | (5.98M) | 8.42M | (4.05M) |
Elicio Therapeutics, Inc.
NASDAQ:ELTX
Intrinsic Alpha fair value
Locked
Current Price
$2.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.